Novartis Warns of Skin Problems with Epilepsy Drug

	Tweet

Novartis AG’s epilepsy drug Trileptal has a new warning about life-threatening skin reactions reported by patients who took the medicine, the company and the Food and Drug Administration said on Tuesday.

“Such serious skin reactions may be life-threatening, and some patients have required hospitalization with very rare reports of fatal outcome,” Novartis said in a letter to physicians that was posted on the FDA Web site.

The problems, reported in both adults and children, included two serious skin disorders called Toxic epidermal necrolysis and Stevens-Johnson syndrome.

The reported rate of those conditions among Trileptal patients was three to 10 times higher than what would be expected in the general population, the Novartis letter said.

“Therefore, if a patient develops a skin reaction while taking Trileptal, consideration should be given to discontinuing Trileptal use and prescribing another anti-epileptic medication,” the company said.

Trileptal is approved for treating partial seizures in adults and children ages 4 to 16 with epilepsy.

A “limited number” of other life-threatening reactions involving multiple organs also have been reported following the start of Trileptal therapy, Novartis said. Symptoms varied but included fever, rash and liver and kidney inflammation. 

RELATED STORIES:
UK agency proposes ban on Alzheimer’s drugs   Irish court delays ruling in Roche acne drug case   Houston man sues Pfizer for Viagra blindness   Novo says Victoza not to blame for 2 Japan deaths   Some Ethnic Groups More Susceptible to Adverse Drug Reactions   No increase in stroke risk with non-aspirin NSAIDs   Parents too often unaware of child’s drug abuse   FDA Urges Lowering Maximum Daily Dose Of Celexa   Other Vioxx-like drugs also risky for heart   Methotrexate in early pregnancy may not cause defects   Celecoxib Can Adversely Affect Heart Rhythm   Intercell kills diarrhea vaccine after study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]